Life Biosciences' ER-100 gene therapy aims to restore vision by rejuvenating retinal neurons through epigenetic reprogramming
By
Neetika Walter
Summary
Life Biosciences has developed ER-100, a first-ever experimental gene therapy that aims to restore vision by rejuvenating damaged retinal neurons. The therapy uses the company's Partial Epigenetic Reprogramming platform, which employs three Yamanaka transcription factors (OCT-4, SOX-2, and KLF-4, collectively known as OSK) to reverse cellular aging signatures without altering DNA. This approach targets neurons that do not naturally regenerate, offering potential treatments for conditions like open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. In preclinical studies, ER-100 was delivered directly into the eye.
Source
bskyLife Biosciences' ER-100 gene therapy aims to restore vision by rejuvenating retinal neurons through epigenetic reprogramminginterestingengineering.comKey quotes
· 3 pulledThese neurons do not naturally regenerate, making disorders such as open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy especially difficult to treat.
The therapy emerged from Life Bio's Partial Epigenetic Reprogramming platform, which alters biochemical markers that control gene expression without changing DNA itself.
The method uses controlled expression of three Yamanaka transcription factors, OCT-4, SOX-2, and KLF-4, collectively known as OSK, to rewind cellular aging signatures.
You might also wanna read
Life Biosciences Conducts First Gene Therapy Trial to Reverse Cellular Aging in Patient with Glaucoma
Life Biosciences, a Boston-based biotech startup, has conducted the world's first gene therapy on a living patient aimed at reversing cellul
popularmechanics.com·3h ago
OpenAI and Retro Biosciences Develop AI Model That Achieves 50x Improvement in Stem Cell Reprogramming
OpenAI collaborated with Retro Biosciences to develop GPT-4b micro, a specialized AI model for protein engineering. The AI-designed proteins
openai.com·10mo ago
FDA Approves First Dual-AAV Gene Therapy for Genetic Hearing Loss Under Priority Voucher Program
The FDA has approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy for trea
FDA·2mo ago
Extracellular Vesicles as Anti-Aging Therapeutics: Mechanisms, Bioengineering, and Clinical Perspectives
This comprehensive review article systematically examines the anti-aging potential of extracellular vesicles (EVs), focusing on their multif
onlinelibrary.wiley.com·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.